GLG News by Juvederm Users: Cosmetic Dermatologists (US)

ELEVESS received its CE mark approval in Europe. The product is entering a crowded field with no real differentiating factors other than having lidocaine as an anesthetic. To release this product in the US without a partnership with an established company will be very hard. It will not be easy to compete...

There is a consensus in the non-surgical aesthetic medicine arena that Hyaluronic Acid gel fillers are at present the number one choice.Over the last few years I have seen every single biotech company that makes HA for orthopaedics and ophthalmology surgery jumping on the bandwagon of Restylane and...

 Altabax is a member of a new class of antibiotics and is a topical treatment for uncomplicated skin and skin structure infections due to susceptible strains of Staphylococcus aureus and Streptococcus pyogenes. It's to be used twice daily use for a five-day period. Altabax’s unique...

Galderma has partnered with Anika to launch a hyaluronic acid product into the marketplace. It will be the first HA filler to be combined with Lidocaine.However, Medicis (with a 3 1/2 year headstart with Restylane) and Allergan's Juvederm will probably still take the lion's share of the filler market....

For a company that has had its share of rejections and problems with the approval of a phakic IOL (ICL Visian)  that it tried to have enter the US market almost a decade ago, things are not improving much for Staar.  The company recently reported that despite its request over one year ago...

Mutifocal iols are currently used to try to correct distance and near vision.  While patients are often pleased by their improved near vision without glasses, many complain of poor optical quality for distance vision.  Due to great out of pocket costs and poor quality of vision under some...

These cases may just be an isolated incident and the report of one or two cases clearly creates attention to the infection and awareness for further cases. In the over 11 years since laser vision correction has been approved in the USA we have not seen much incidence of these infections, so we must...

An argument can be made for LASEK over LASIK for the initial laser treatment in some patients, but the re-lifting of the lasik flap and performing a laser re treatment is the management of choice in almost all cases of post lasik myopic regression. An exception would be if the cornea is too thin or...

The phase 2 data for Incyclinide indicate a modest benefit over placebo for the 20 mg dose only, which drops off at 12 weeks. This drug will need a higher dose for efficacy. The premise behind a non antimicrobial antibiotic type medication is valid and intriguing. The next trial results are important...

This article describes the perspective of a retinal specialist on the Avastin/Lucentis controversy.  In mid-February the National Institutes of Health announced that it would conduct a head to head trial comparing the effectiveness of Lucentis and Avastin for the treatment of wet  age...